BioLife Solutions Updates Earnings Call Information

5/8/25 4:32:00 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $BLFS alert in real time by email

BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally.

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Media & Investor Relations

At the Company

Troy Wichterman

Chief Financial Officer

(425) 402-1400

[email protected]

Investors

Alliance Advisors IR

Jody Cain

(310) 691-7100

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-updates-earnings-call-information-302450601.html

SOURCE BioLife Solutions, Inc.

Get the next $BLFS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BLFS

Date	Price Target	Rating	Analyst
9/30/2024	$29.00	Buy	H.C. Wainwright
4/4/2024	$22.00	Buy	Jefferies
7/11/2023	$29.00	Buy	Craig Hallum
4/25/2022	$28.00	Perform → Outperform	Oppenheimer
10/19/2021	$61.00	Buy	B. Riley Securities
10/15/2021	$64.00	Outperform	Cowen
8/13/2021	$50.00 → $60.00	Overweight	Keybanc

More analyst ratings

$BLFS
Press Releases

Fastest customizable press release news feed in the world

BioLife Solutions Updates Earnings Call Information
BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally. About BioLife Solutions BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our exper
5/8/25 4:32:00 PM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
BioLife Solutions Reports First Quarter 2025 Financial Results
Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi
5/8/25 4:03:00 PM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati
4/30/25 8:03:00 AM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

BioLife Solutions Reports First Quarter 2025 Financial Results
Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi
5/8/25 4:03:00 PM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati
4/30/25 8:03:00 AM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. The acquisition further strengthens BioLife's position a
4/7/25 8:03:00 AM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$BLFS
Leadership Updates

Live Leadership Updates

BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an
3/18/25 8:30:00 AM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is
12/16/24 8:11:00 AM ET
$BLFS
$RGEN
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.
8/25/22 8:03:00 AM ET
$BLFS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care